首页> 外文期刊>RSC Advances >Molecularly imprinted polymer nanoparticles for olanzapine recognition: application for solid phase extraction and sustained release
【24h】

Molecularly imprinted polymer nanoparticles for olanzapine recognition: application for solid phase extraction and sustained release

机译:用于奥烷扎滨识别的分子印迹聚合物纳米颗粒:固相提取和持续释放的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Recently, scientists have drawn more attention to polymeric nanoparticles as potential drug carriers. In this study, we synthesized high selective imprinted polymer nanoparticles using olanzapine as the template. The aim of this study was to prepare efficient imprinted polymer nanoparticles from an olanzapine template for the controlled release of olanzapine as a therapeutic drug for central nervous system (CNS) diseases at different pH values, and solid-phase extraction (SPE) as the sample clean-up technique combined with high-performance liquid chromatography (HPLC). The morphology of the nanoparticles was determined using scanning electron microscopy (SEM) images. Drug release, binding properties and dynamic light scattering (DLS) of the molecularly imprinted polymers (MIPs) were studied in this investigation. The adsorption isotherm was fitted with Langmuir and Freundlich models. The performance of the MIPs for the controlled release of olanzapine was assessed in two different media (SDS 1% and PBS). Results revealed that the MIPs have potential application in controlled drug release. Moreover, cytotoxicity of the MIP nanoparticles was measured on a NIH/3T3 cell line using a MTT method. Furthermore, the MIPs were applied to extract olanzapine from human blood plasma samples. The limit of detection (LOD) and limit of quantification (LOQ) were evaluated and were 0.18 mu g L-1 and 0.39 mu g L-1, respectively. These results collectively illustrate that MIP nanoparticles can be employed as an efficient technique for the extraction of the olanzapine from human plasma.
机译:最近,科学家们更加关注聚合物纳米颗粒作为潜在药物载体。在该研究中,我们使用奥氮滨作为模板合成高选择性印迹聚合物纳米颗粒。本研究的目的是从奥氮翼模板中制备有效的印迹聚合物纳米颗粒,用于将奥氮滨的控制释放作为不同pH值的中枢神经系统(CNS)疾病的治疗药物,以及作为样品的固相萃取(SPE)清理技术与高效液相色谱相结合(HPLC)。使用扫描电子显微镜(SEM)图像测定纳米颗粒的形态。在该研究中研究了分子印迹聚合物(MIPS)的药物释放,结合性质和动态光散射(DLS)。吸附等温线配有Langmuir和Freundlich模型。在两种不同培养基中评估用于控制奥氮藻的控制释放的MIPS的性能(SDS 1%和PBS)。结果表明,MIPS在受控药物释放中具有潜在的应用。此外,使用MTT方法在NIH / 3T3细胞系上测量MIP纳米颗粒的细胞毒性。此外,施用MIPS以从人血浆样品中提取奥氮滨。评价检测极限(LOD)和定量限制(LOQ),分别为0.18μg1-1和0.39μg1-1。这些结果共同说明了MIP纳米颗粒可以作为从人血浆中提取奥氮藻的有效技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号